Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy
Main findingResult — go to the resultDecrease in % time ≥250 mg/dL 16.9 %Authors' conclusion
Findings from this feasibility trial of AID in adults with type 2 diabetes with suboptimal glycemic outcomes justify further evaluation of this technology in this population.
Study context
- Population
- Adults with T2D on basal-only or basal-bolus insulin injections, baseline HbA1c ≥8% (≥64 mmol/mol); mean age 61 ± 8 years, baseline HbA1c 9.4% ± 0.9%, diabetes duration 19 ± 9 years
- Participants
- 24 adults
- Comparison
- Automated insulin delivery (AID) vs prior standard therapy
- Outcome
- Primary safety outcomes: % time with sensor glucose ≥250 mg/dL and <54 mg/dL during AID
Methodological detailsmulticenter, outpatient, Antihyperglycemic agents continued at clinician discretion, Basal-only users used AID in manual mode for 2 weeks before starting AID
- Multicenter
- Outpatient
- Antihyperglycemic agents continued at clinician discretion
- Basal-only users used AID in manual mode for 2 weeks before starting AID
Main finding
As reported in the abstract
Decrease in % time ≥250 mg/dL
16.9 %
P < 0.0001
Further findings
HbA1c change with AID
- HbA1c decreased (± SD), P < 0.0001
- 1.3% ± 0.7% (14 ± 8 mmol/mol)
TIR (70-180 mg/dL) change with AID
- TIR increased, P < 0.0001
- 21.9% ± 15.2%
Total daily insulin and BMI
- No significant change in total daily insulin or BMI with AID
Original publication
Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy. Diabetes Care. Published 14 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →